Guidant shareholder suit dismissed
This article was originally published in The Gray Sheet
Executive Summary
United States District Court in Indianapolis dismisses March 27 a shareholder class action suit against cardiac device maker Guidant alleging breach of fiduciary duties and failure to disclose material information prior to a series of merger negotiations that culminated in Guidant's acquisition by Boston Scientific in 2006. What the plaintiffs called a "bidding fiasco" took place amid high-profile recalls of certain Guidant pacemakers and implantable defibrillators (1"The Gray Sheet" July 24, 2006, p. 10). District Judge Sarah Evans Barker, who issued the ruling, also dismissed in February securities class action proceedings against the company. Plaintiffs in both actions retain the right to appeal
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.